Public Market Listing
4503 TSE
TSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (15 total) 15 Total Assets
4 Approved
4 Phase 3 / Filed
7 Phase 1–2 / Early
14 Diseases
Disease: All diseases (15) Non-Small Cell Lung Cancer (5) Gastric Cancer (2) Chronic Kidney Disease (2) Prostate Cancer (2) Age-Related Macular Degeneration (1) Bladder Cancer (1) Acute Myeloid Leukemia (1) Irritable Bowel Syndrome (1) Hyperphosphatemia (1) Myelodysplastic Syndromes (1) Pancreatic Ductal Adenocarcinoma (1) X-Linked Myotubular Myopathy (1) Pompe Disease (1) Geographic Atrophy (1)
Stage: All stages (15) Approved / Phase 4 (4) Phase 3 / Filed (4) Phase 2 Phase 1 / Preclinical
Quick filter: All (15) Non-Small Cell Lung Cancer (5) Gastric Cancer (2) Chronic Kidney Disease (2) Prostate Cancer (2) Age-Related Macular Degeneration (1)
Showing 15 of 15 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved Complement C5 Other
Age-Related Macular Degeneration
Approved Nectin-4 Antibody–drug conjugate
Non-Small Cell Lung Cancer Bladder Cancer
Approved FLT3 Small molecule
Non-Small Cell Lung Cancer Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia Approved Guanylate cyclase-C (GC-C) Peptide
Irritable Bowel Syndrome
Irritable Bowel Syndrome with Constipation Phase 3 Claudin 18.2 x CD3 Multispecific antibody
Phase 3 Phosphate binder Small molecule
Chronic Kidney Disease Hyperphosphatemia
Phase 3 HIF prolyl hydroxylase (HIF-PH1/2/3) Small molecule
Chronic Kidney Disease Myelodysplastic Syndromes
Phase 3 KRAS G12D Small molecule
Non-Small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma
Phase 2 CYP17 lyase Small molecule
Phase 1/2 MTM1 (myotubularin) Gene therapy / editing
X-Linked Myotubular Myopathy
Phase 1/2 Claudin 18.2 (CLDN18.2) Antibody–drug conjugate
Non-Small Cell Lung Cancer Gastric Cancer
Phase 1/2 GAA (acid alpha-glucosidase) Gene therapy / editing
Phase 1 Pan-KRAS Small molecule
Non-Small Cell Lung Cancer
Phase 1 — Cell therapy
Phase 1 PSMA x CD3 Multispecific antibody
Upcoming events (16 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (1) December 2026 (1) ASP546C Phase 1/2 Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic, Biliary Tract Cancer … Est. primary completion 2026-12-30 ·
NCT06792435 ·
CT.gov ↗ What to watch
2027 (4) October 2027 (2) ASP2957 Phase 1/2 X-Linked Myotubular Myopathy Est. primary completion 2027-10-31 ·
NCT07052929 ·
CT.gov ↗ What to watch
November 2027 (1) December 2027 (1) Enfortumab Vedotin Phase 1/2 Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma Est. primary completion 2027-12-28 ·
NCT07421700 ·
CT.gov ↗ What to watch
2028 (1) July 2028 (1) Gilteritinib Phase 1/2 Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia Est. primary completion 2028-07-31 ·
NCT05520567 ·
CT.gov ↗ What to watch
2029 (3) June 2029 (1) Enfortumab Vedotin Phase 1/2 Locally Advanced or Metastatic Malignant Solid Tumors Est. primary completion 2029-06-30 ·
NCT07287995 ·
CT.gov ↗ What to watch
July 2029 (1) ASP546C Phase 1/2 Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma Est. primary completion 2029-07-31 ·
NCT07488676 ·
CT.gov ↗ What to watch
August 2029 (1) Setidegrasib Phase 3 Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma Est. primary completion 2029-08-31 ·
NCT07409272 ·
CT.gov ↗ What to watch
2030 (3) March 2030 (1) Enfortumab Vedotin Phase 3 Urothelial Cancer, Urinary Bladder Neoplasms Est. primary completion 2030-03-31 ·
NCT07566156 ·
CT.gov ↗ What to watch
June 2030 (1) Setidegrasib Phase 3 Non-small Cell Lung Cancer (NSCLC) Est. primary completion 2030-06-30 ·
NCT07566052 ·
CT.gov ↗ What to watch
September 2030 (1) 2031 (1) February 2031 (1) ASP2138 Phase 3 Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma Est. primary completion 2031-02-28 ·
NCT07673887 ·
CT.gov ↗ What to watch
2032 (2) May 2032 (1) Abiraterone decanoate Phase 2 Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer Est. primary completion 2032-05-31 ·
NCT07005154 ·
CT.gov ↗ What to watch
July 2032 (1) ASP2957 Phase 1/2 X-linked Myotubular Myopathy Est. primary completion 2032-07-31 ·
NCT07876804 ·
CT.gov ↗ What to watch
2035 (1) See the full readout calendar ↗
Regulatory and conference events (18) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
23 October 2026 Approval Enfortumab Vedotin European Commission expands Padcev approval to resectable MIBC 7 July 2026 Filing accepted Enfortumab Vedotin NMPA accepts BLA for Padcev plus Keytruda in muscle-invasive bladder cancer 20 April 2026 Filing accepted Enfortumab Vedotin FDA accepts sBLA for perioperative PADCEV + Keytruda in MIBC 20 April 2026 Priority review Enfortumab Vedotin FDA grants Priority Review to PADCEV + Keytruda sBLA in MIBC 7 April 2026 FDA action date Enfortumab Vedotin PDUFA target action date set for April 7, 2026 9 March 2026 Topline result Gilteritinib (Xospata) Phase 3 HOVON 156 / AMLSG 28-18 / PASHA (NCT04027309) missed its overall survival primary endpoint Astellas Pharma Inc. and HOVON ·
Source ↗ 17 December 2025 Topline result Enfortumab Vedotin EV-304 Phase 3 interim topline results positive 22 October 2025 Filing accepted Enfortumab Vedotin FDA accepts the PADCEV plus KEYTRUDA sBLA in MIBC and grants Priority Review 18 October 2025 Topline result Enfortumab Vedotin EV-303 Phase 3 positive topline results for PADCEV plus KEYTRUDA in MIBC 12 February 2025 Approval Avacincaptad pegol FDA approves expanded IZERVAY label without limit on dosing duration The 12 most recent of 18 past events are shown.
Financial reports Annual history (6 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-FY $14.1B $2.1B $1.8B — report ↗
View 5 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $12.6B $2.2B $1.3B — report ↗ 2024-FY $11.0B $2.0B $2.2B — report ↗ 2023-FY $11.2B $2.0B $2.8B — report ↗ 2022-FY $11.5B $2.2B $2.6B — report ↗ 2021-FY $11.8B $2.1B $3.0B — report ↗